From the Guidelines
Exposure to Cladosporium herbarum is associated with allergic reactions, respiratory issues, and skin problems, with symptoms including sneezing, runny or stuffy nose, itchy or watery eyes, and throat irritation. The symptoms of Cladosporium herbarum exposure can vary depending on individual sensitivity and the concentration of mold spores.
Common Symptoms
- Sneezing
- Runny or stuffy nose
- Itchy or watery eyes
- Throat irritation
- Skin rashes or hives
Respiratory Issues
In individuals with asthma, Cladosporium exposure can trigger:
- Wheezing
- Chest tightness
- Coughing
- Shortness of breath Those with compromised immune systems may experience more severe respiratory infections, while people with chronic lung conditions might develop hypersensitivity pneumonitis, characterized by:
- Flu-like symptoms
- Fever
- Chills
- Dry cough
- Shortness of breath Although a study on allergen immunotherapy suggests that allergen immunotherapy with fungi might be effective 1, the primary concern is reducing exposure to prevent symptoms. Reducing exposure by controlling indoor humidity, improving ventilation, and cleaning visible mold can help manage symptoms, while antihistamines, nasal corticosteroids, or bronchodilators may provide relief depending on symptom type and severity.
From the Research
Symptoms Associated with Cladosporium herbarum Exposure
The symptoms associated with Cladosporium herbarum exposure include:
- Allergic reactions, such as rhinitis and ocular symptoms 2, 3
- Severe involvement of the lower respiratory tract, including asthma 2, 4
- Histamine release from human basophils, leading to symptoms such as itching, sneezing, and congestion 2
- Increased IgE reactivity, which can lead to allergic inflammation and hyper-reactivity 2, 3
- Airway hyperreactivity and remodelling, which can lead to chronic respiratory problems 5
Specific Symptoms Reported in Studies
- Asthma score and peak flow changes 4
- Consumption of antiasthmatic medication 4
- Large local reactions and episodes of asthma during dose-increase phase of immunotherapy 4
- Systemic reactions, including severe reactions 4
- Eosinophil-rich airway inflammation, airway hyperreactivity, and airway wall modifications 5